# Statins for Digital Ulcers and Raynaud's Phenomenon in systemic sclerosis

Submission date 05/12/2007	<b>Recruitment status</b> No longer recruiting	[] Pros [] Prote
<b>Registration date</b> 10/12/2007	<b>Overall study status</b> Completed	[_] Stati [X] Resu
Last Edited 01/10/2008	<b>Condition category</b> Musculoskeletal Diseases	[] Indiv

spectively registered

tocol

cistical analysis plan

ults

vidual participant data

#### Plain English summary of protocol

Not provided at time of registration

### Contact information

Type(s) Scientific

Contact name Dr Anna Abou-Raya

**Contact details** 12 Heliopolis Street Camp Cesar Alexandria Egypt

# Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

Secondary identifying numbers N/A

# **Study information**

Scientific Title

Statins: a potentially useful therapeutic option in the management of systemic sclerosis-related Raynaud's phenomenon and digital ulcers

#### Acronym

SDURP

#### Study objectives

Systemic Sclerosis (SSc) is a chronic connective tissue disorder characterised by excessive cutaneous and visceral fibrosis, an aberrant immune activation and widespread, pronounced alterations in the microvasculature with structural and functional vasculopathy. Statins have an effect on endothelial dysfunction and thus may help ameliorate Raynaud's phenomenon and digital ulcers characteristic of SSc.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Ethics approval received from the Ethics Committee of the Faculty of Medicine, University of Alexandria on the 13th of September, 2005.

#### **Study design** Randomised double-blind placebo-controlled trial

### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

Study setting(s) Hospital

### Study type(s)

Treatment

#### Participant information sheet

# Health condition(s) or problem(s) studied

Systemic Sclerosis (SSc)

#### Interventions

The patients are divided into 2 groups: Group 1: assigned to receive 40 mg/day of atorvastatin for four months Group 2: assigned to identical placebo tablets for four months

Seventy-five healthy age-sex-matched volunteers serve the purpose of controls.

#### Intervention Type Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Atorvastatin

#### Primary outcome measure

The primary outcome measure is the number of new digital ulcers occurring during the study period, measured monthly.

#### Secondary outcome measures

- 1. The Scleroderma Health Assessment Questionnaire subsets for dressing/grooming (SHAQ-DI)
- 2. Eating and hand grip
- 3. Assessment of safety and tolerability of the atorvastatin therapy

All secondary outcomes are measured monthly.

Overall study start date 30/09/2005

**Completion date** 05/05/2006

# Eligibility

#### Key inclusion criteria

 Raynaud's phenomenon
 A history of a documented digital ulcer secondary to SSc within the last 12 months despite ongoing vasodilator therapy
 Aged between 25 - 60 years, both male and female

Participant type(s)

Patient

**Age group** Adult

**Sex** Both

**Target number of participants** 80

#### Key exclusion criteria

- 1. Smoking
- 2. Diabetes mellitus
- 3. Hypercholesterolaemia
- 4. Hypertension
- 5. Cardiac insufficiency
- 6. Coexisting hepatic and renal diseases and drugs known to interact with statins

Date of first enrolment 30/09/2005

Date of final enrolment 05/05/2006

### Locations

**Countries of recruitment** Egypt

**Study participating centre 12 Heliopolis Street** Alexandria Egypt

### Sponsor information

**Organisation** University of Alexandria (Egypt)

Sponsor details Faculty of Medicine 12 Heliopolis Street Camp Cesar Alexandria Egypt -+20 (0)3 5924035 annaaraya@yahoo.com

**Sponsor type** University/education

Website http://www.alexmed.org

ROR https://ror.org/00mzz1w90

### Funder(s)

**Funder type** Other

**Funder Name** Investigator intiated and funded (Egypt)

### **Results and Publications**

**Publication and dissemination plan** Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Results article</u>	results	01/09/2008		Yes	No